Vertex Pharmaceuticals Inc / Ma (VRTX) Files Form 4 Insider Selling : Joshua S Boger Sells 5,130 Shares

Vertex Pharmaceuticals Inc / Ma (VRTX): Joshua S Boger , director of Vertex Pharmaceuticals Inc / Ma sold 5,130 shares on Apr 20, 2016. The Insider selling transaction was reported by the company on Apr 22, 2016 to the Securities and Exchange Commission. The shares were sold at $84.38 per share for a total value of $431,416.81 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 15, 2016, Joshua S Boger (director) sold 5,130 shares at $84.78 per share price.On Feb 4, 2016, Ian F Smith (EVP & CFO) sold 12,084 shares at $91.32 per share price.Also, On Feb 4, 2016, Paul M Silva (SVP & Corp Controller) sold 5,062 shares at $91.63 per share price.On Feb 4, 2016, Amit Sachdev (EVP, Policy, Access & Value) sold 10,166 shares at $91.38 per share price.

Vertex Pharmaceuticals Incorporated: On Wednesday, Apr 20, 2016 heightened volatility was witnessed in Vertex Pharmaceuticals Incorporated which led to swings in the share price. The shares opened for trading at $84.39 and hit $87.49 on the upside , eventually ending the session at $86.81, with a gain of 3.21% or 2.7 points. The heightened volatility saw the trading volume jump to 17,31,603 shares. The 52-week high of the share price is $143.45 and the company has a market cap of $21,389 M . The 52-week low of the share price is at $75.9.

Vertex Pharmaceuticals Incorporated Money Flow Index Chart

Company has been under the radar of several Street Analysts.Vertex Pharmaceuticals Incorporated is Reiterated by Stifel to Buy while Lowering the Price Target of the company shares to $ 108 from a previous price target of $140 . The Rating was issued on Apr 1, 2016.Vertex Pharmaceuticals Incorporated is Reiterated by RBC Capital Mkts to Outperform while Lowering the Price Target of the company shares to $ 135 from a previous price target of $145 . The Rating was issued on Mar 18, 2016.Vertex Pharmaceuticals Incorporated is Reiterated by Argus to Buy while Lowering the Price Target of the company shares to $ 140 from a previous price target of $154 . The Rating was issued on Feb 4, 2016.Vertex Pharmaceuticals Incorporated is Upgraded by Jefferies to Buy. Earlier the firm had a rating of Hold on the company shares. The Rating was issued on Feb 1, 2016.

Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering developing manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertex’s business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs including programs in the areas of oncology and neurology. The Company’s product candidates include KALYDECO (ivacaftor) Lumacaftor in combination with Ivacaftor VX-661 in combination with Ivacaftor VX-803 VX-970 and VX-222. The Company’s product KALYDECO is available in the market.

Leave a Reply

Vertex Pharmaceuticals Incorporated - Is it time to Sell?

Top Brokerage Firms are advising their investors on Vertex Pharmaceuticals Incorporated. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.